<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103647</url>
  </required_header>
  <id_info>
    <org_study_id>ID-PRMD-1202</org_study_id>
    <nct_id>NCT02103647</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation</brief_title>
  <official_title>A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics profiles of pregabalin sustained
      release tablet (300mg) to immediate release capsule(150mg * 2) while multiple dosing.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure blood concentration of pregabalin</measure>
    <time_frame>0~4day / 14~18day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation</measure>
    <time_frame>0~25day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Immediate release capsule(lyrica capsule 150mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate release capsule repeat treatment for 3days under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sustained release tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sustained release tablet repeat treatment for 3days under fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate release capsule(lyrica 150mg * 2/day)</intervention_name>
    <description>Immediate release capsule</description>
    <arm_group_label>Immediate release capsule(lyrica capsule 150mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sustained release tablet</intervention_name>
    <description>sustained release tablet</description>
    <arm_group_label>sustained release tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19~44 aged healthy adult.

          -  someone tho has at least 50kg body weight and ideal body weight Â±20%

        Exclusion Criteria:

          -  someone has acute symptom at screening phase

          -  someone has any disease or symptoms which is clinically significant

          -  someone had been determined during healthy examination in screening period

          -  AST or ALT &gt; 1.25 times than normal

          -  Total bilirubin &gt; 1.5 times than normal

          -  someone who has a history of allergy, anaphylaxis, drug abuse or misuse.

          -  someone who had enrolled to other clinical trial within the last 60 days.

          -  someone who had donated blood within the last 60 days.

          -  someone who can't take a meal derived from this trial.

          -  someone who has taken abnormal meals like which can affect to drug ADME

          -  someone who has taken other ETC drugs or oriental drugs within the last 14 days, Or
             OTC drugs within the last 7 days

          -  someone who has taken caffein continuously (coffee or green tea more than 5 cups per a
             day) or took caffein since 24hours before.

          -  someone who has taken alcohol more than 30g/day or smoked more than 10 piece of
             tobacco/day.

          -  someone who has galactose intolerance, Lapp lactase deficiency or glucose-galactose
             malabsorption.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic medical center</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuropathic pain</keyword>
  <keyword>pregabalin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

